RS53408B2 - Farmaceutska kompozicija ibuprofena za injekciju - Google Patents

Farmaceutska kompozicija ibuprofena za injekciju

Info

Publication number
RS53408B2
RS53408B2 RS20140366A RSP20140366A RS53408B2 RS 53408 B2 RS53408 B2 RS 53408B2 RS 20140366 A RS20140366 A RS 20140366A RS P20140366 A RSP20140366 A RS P20140366A RS 53408 B2 RS53408 B2 RS 53408B2
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
ibuprofen
injection
composition
concentration
Prior art date
Application number
RS20140366A
Other languages
English (en)
Inventor
Andéchaga Ignacio Ortúzar
Gutiérrez Mario Ortúzar
Original Assignee
Genfarma Laboratorio S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43589415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS53408(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genfarma Laboratorio S L filed Critical Genfarma Laboratorio S L
Publication of RS53408B publication Critical patent/RS53408B/sr
Publication of RS53408B2 publication Critical patent/RS53408B2/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

Patentni zahtevi
1. Farmaceutska kompozicija ibuprofena za injekciju koja sadrži vodeni rastvor ibuprofena i trometamola, pri čemu je koncentracija ibuprofena između 2 i 6 mg/mi, dok je koncentracija trometamola između 1,8 i 5,8 mg/mi, i pH je između 8,0 i 9,0
2. Farmaceutska kompozicija ibuprofena za injekciju prema zahtevu 1, pri čemu je koncentracija ibuprofena oko 4 mg/ml.
3. Farmaceutska kompozicija prema zahtevima 1 ili 2, pri čemu je koncentracija trometamola približno 3,8 mg/ml.
4. Farmaceutska kompozicija prema bilo kom od prethodnih zahteva 1 do 3 koja se može sterilizovati toplotom autoklaviranjem па temperaturi između 110°C i 130°C, tokom vremenskog perioda između 2 i 190 minuta,
5. Farmaceutska kompozicija prema zahtevu 4, pri čemu se kompozicija može sterilizovati toplotom autoklaviranjem na temperaturi od 121°С, tokom 15 minuta.
6. Farmaceutska kompozicija ibuprofena za injekciju prema bilo kom od prethodnih zahteva 1 do 5, pri čemu, kada je kompozicija stavljena u kontejnere od stakla, onda je pH između 8,0 i 9,0.
7. Farmaceutska kompozicija ibuprofena za injekciju prema bilo kom od prethodnih zahteva 1 do 5, pri čemu, kada je kompozicija stavljena u kontejnere od polietilena, onda je pH između 8,0 i 9,0.
8. Farmaceutska kompozicija ibuprofena za injekciju prema bilo kom od prethodnih zahteva 1 do 5, pri čemu.
kada je kompozicija stavljena u kontejnere od polipropilena, onda je pH između 8,0 i 9,0.
9. Farmaceutska kompozicija ibuprofena za injekciju prema bilo kom od prethodnih zahteva 1 do 5. pri čemu, kada je kompozicija stavljena u kontejnere od PVC-a, onda je pH između 8,0 i 9,0.
10. Farmaceutska kompozicija prema bilo kom od prethodnih zahteva, pri čemu je pH oko 8,5.
11. Farmaceutska kompozicija prema bilo kom od prethodnih zahteva, koja dalje sadrži so u količini koja je neophodna da kompozicija dobije osmolalnost od oko 300 mOsm/kg.
12. Farmaceutska kompozicija prema zahtevu 11, pri čemu je so NaCI u koncentraciji od približno 7,7 mg/ml.
13. Kompozicija prema bilo kom od zahteva 1 do 12 za primenu u lečenju bola, zapaljenja ili groznice.
14. Kompozicija prema zahtevu 13:koja je stavljena u kontejnere od 100 ml ili 200 ml.
15. Primena farmaceutske kompozicije prema bilo kom od zahteva 1 do 12 za dobijanje leka za lečenje bola, zapaljenja ili groznice.
RS20140366A 2010-05-18 2011-05-18 Farmaceutska kompozicija ibuprofena za injekciju RS53408B2 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/ES2010/070330 WO2011144766A1 (es) 2010-05-18 2010-05-18 Composición farmacéutica de ibuprofeno para inyección
EP11720479.2A EP2571488B2 (en) 2010-05-18 2011-05-18 Pharmaceutical composition of ibuprofen for injection
PCT/EP2011/058087 WO2011144677A1 (en) 2010-05-18 2011-05-18 Pharmaceutical composition of ibuprofen for injection

Publications (2)

Publication Number Publication Date
RS53408B RS53408B (sr) 2014-10-31
RS53408B2 true RS53408B2 (sr) 2018-06-29

Family

ID=43589415

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140366A RS53408B2 (sr) 2010-05-18 2011-05-18 Farmaceutska kompozicija ibuprofena za injekciju

Country Status (35)

Country Link
US (1) US9114165B2 (sr)
EP (1) EP2571488B2 (sr)
JP (1) JP6018048B2 (sr)
KR (1) KR101770808B1 (sr)
CN (1) CN102892410B (sr)
AU (1) AU2011254583B2 (sr)
BR (1) BR112012029171B1 (sr)
CA (1) CA2798575C (sr)
CL (1) CL2012003119A1 (sr)
CO (1) CO6650419A2 (sr)
CR (1) CR20120559A (sr)
CY (1) CY1115394T1 (sr)
DK (1) DK2571488T4 (sr)
EC (1) ECSP12012274A (sr)
ES (1) ES2478491T5 (sr)
HR (1) HRP20140622T4 (sr)
IL (1) IL222497A0 (sr)
MA (1) MA34176B1 (sr)
ME (1) ME01834B (sr)
MX (1) MX2012013402A (sr)
MY (1) MY160302A (sr)
NZ (1) NZ602957A (sr)
PE (1) PE20130374A1 (sr)
PH (1) PH12012502274A1 (sr)
PL (1) PL2571488T5 (sr)
PT (1) PT2571488E (sr)
RS (1) RS53408B2 (sr)
RU (1) RU2012154628A (sr)
SG (1) SG185061A1 (sr)
SI (1) SI2571488T2 (sr)
SM (1) SMT201400103B (sr)
TN (1) TN2012000487A1 (sr)
UA (1) UA103290C2 (sr)
WO (2) WO2011144766A1 (sr)
ZA (1) ZA201207948B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072710B2 (en) * 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
CN104323988A (zh) * 2014-11-27 2015-02-04 北京蓝丹医药科技有限公司 一种用于注射的右旋布洛芬药物组合物
CN105055389B (zh) * 2015-08-03 2018-08-10 北京蓝丹医药科技有限公司 一种用于早产儿先天性心脏病的布洛芬药物组合物
CN105997901A (zh) * 2016-07-27 2016-10-12 济南东方开元医药新技术有限公司 小儿注射用布洛芬氨丁三醇冻干粉针组合物及制备方法
KR102927247B1 (ko) * 2018-12-14 2026-02-12 프레제니우스 카비 오스트리아 게엠베하 이부프로펜 및 포스페이트 완충액을 포함하는 비경구 투여용 약학 조성물
CN112526013B (zh) * 2020-11-20 2022-09-06 人福普克药业(武汉)有限公司 超高液相色谱法检测布洛芬药物中有关物质浓度方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19912436A1 (de) * 1999-03-19 2000-09-21 Merckle Gmbh Ibuprofen-Lösung
US20040132823A1 (en) 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
DE60114249T2 (de) 2001-11-02 2006-05-18 Cumberland Pharmaceuticals Inc., Nashville Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
ITMI20040235A1 (it) 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale

Also Published As

Publication number Publication date
IL222497A0 (en) 2012-12-31
PL2571488T3 (pl) 2014-12-31
HRP20140622T4 (hr) 2017-10-06
AU2011254583B2 (en) 2014-04-10
CO6650419A2 (es) 2013-04-15
ECSP12012274A (es) 2013-02-28
RS53408B (sr) 2014-10-31
PE20130374A1 (es) 2013-03-30
AU2011254583A1 (en) 2012-11-08
MX2012013402A (es) 2013-01-17
CN102892410B (zh) 2014-12-10
CY1115394T1 (el) 2017-01-04
MY160302A (en) 2017-02-28
UA103290C2 (ru) 2013-09-25
EP2571488A1 (en) 2013-03-27
TN2012000487A1 (en) 2014-04-01
CA2798575A1 (en) 2011-11-24
BR112012029171B1 (pt) 2021-05-25
BR112012029171A2 (pt) 2017-07-18
US9114165B2 (en) 2015-08-25
ES2478491T5 (es) 2017-11-21
ES2478491T3 (es) 2014-07-22
CA2798575C (en) 2018-08-28
HK1177424A1 (en) 2013-08-23
KR101770808B1 (ko) 2017-08-23
DK2571488T3 (da) 2014-07-14
CL2012003119A1 (es) 2013-06-07
ZA201207948B (en) 2013-06-26
KR20130109007A (ko) 2013-10-07
ME01834B (me) 2014-12-20
CR20120559A (es) 2013-02-15
EP2571488B2 (en) 2017-07-26
EP2571488B1 (en) 2014-06-18
SMT201400103B (it) 2014-09-08
WO2011144766A1 (es) 2011-11-24
US20130231390A1 (en) 2013-09-05
RU2012154628A (ru) 2014-06-27
JP6018048B2 (ja) 2016-11-02
MA34176B1 (fr) 2013-04-03
JP2013529205A (ja) 2013-07-18
SI2571488T2 (sl) 2017-09-29
SG185061A1 (en) 2012-12-28
DK2571488T4 (en) 2017-08-28
SI2571488T1 (sl) 2014-09-30
WO2011144677A1 (en) 2011-11-24
HRP20140622T1 (en) 2014-09-26
CN102892410A (zh) 2013-01-23
PT2571488E (pt) 2014-07-25
PL2571488T5 (pl) 2018-07-31
NZ602957A (en) 2014-09-26
PH12012502274A1 (en) 2013-02-04

Similar Documents

Publication Publication Date Title
RS53408B2 (sr) Farmaceutska kompozicija ibuprofena za injekciju
HRP20171939T1 (hr) Formulacija protutijela i režimi terapije
SI2648520T1 (en) Dexmedetomidine premix formulation
HRP20201948T1 (hr) Pripravci inhibitora dopa-dekarbokilaze
HRP20210980T1 (hr) Stabilna bez konzervansa midrijatska i protuupalna otopina za injekciju
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
HRP20161311T1 (hr) Tekući farmaceutski pripravak
HRP20180514T1 (hr) Kontinuirana primjena l-dopa, inhibitora dopa dekarboksilaze, inhibitora katekol-o-metiltransferaze i sastava za isto
SI2709613T1 (en) Procedures for the treatment of HCV
BR112012013093A2 (pt) ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
BRPI1013237A2 (pt) formulação aquosa estável, estéril, forma de dosagem unitária farmacêutica, recipiente vedado, kit, métodos para tratar um distúrbio ou doença de células b em um humano, para esgotar células b que expressam cd-19 em um paciente humano, e para intensificar a estabilidade de armazenamento de uma formulação aquosa, e, processo para preparar uma formulação
BR112014028600A8 (pt) Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
BR112014022451A2 (pt) lipídios aminoácido vetorizadores, sistema veículo, seu uso, e composição farmacêutica
BR112013032217A2 (pt) "anticorpo anti-nkg2a, ou fragmento de ligação de antígeno do mesmo, seu usos, e formulação farmacêutica".
RU2011121612A (ru) Инъекционная композиция полидезоксирибонуклеотидов для лечения костно-суставных заболеваний
BR112013026661A2 (pt) método de entrega de vacina
JP2015535237A5 (sr)
BR112016009809A2 (pt) composições de fosfato de cálcio amorfo substituído por magnésio e seus usos
RU2017112303A (ru) Способ применения комбинации нового производного гидроксамовой кислоты и антибактериального вещества
TN2009000088A1 (en) Packaging system for pharmaceutical compositions and kit for intravenous administration
GT200900236A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopopril-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden esta formas.-
BR112014030615A2 (pt) recipiente de múltiplos compartimentos para líquidos biológicos
CN104367507A (zh) 一种皮肤护理液及其制备方法
TN2015000150A1 (en) Stable injectable composition containing diclofenac and thiocolchicoside